Gilead Sciences

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
The Company's portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Company Growth (employees)
Foster City, US
Size (employees)
9,000 (est)
Gilead Sciences was founded in 1987 and is headquartered in Foster City, US

Key People/Management at Gilead Sciences

John Milligan

John Milligan

Kevin Young

Kevin Young


Gilead Sciences Office Locations

Gilead Sciences has offices in Foster City, Fremont, Oceanside, San Dimas and in 2 other locations
Foster City, US (HQ)
333 Lakeside Dr
Branford, US
36 E Industrial Rd
Fremont, US
7601 Dumbarton Cir
Oceanside, US
4049 Avenida De La Plata
San Dimas, US
650 Cliffside Dr
Seattle, US
199 E Blaine St
Show all (6)

Gilead Sciences Financials and Metrics

Gilead Sciences Financials

Gilead Sciences's revenue was reported to be $30.4 b in FY, 2016

Revenue (Q2, 2017)

7.1 b

Gross profit (Q2, 2017)

6 b

Gross profit margin (Q2, 2017), %


Net income (Q2, 2017)

3.1 b

EBIT (Q2, 2017)

4.3 b

Market capitalization (22-Dec-2017)

95.9 b

Cash (30-Jun-2017)

8.7 b
Gilead Sciences's current market capitalization is $95.9 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


11.2 b24.9 b32.6 b30.4 b

Revenue growth, %


Cost of goods sold

2.9 b3.8 b4 b4.3 b

Gross profit

8.3 b21.1 b28.6 b26.1 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


2.8 b5 b6.5 b6 b7.6 b8.2 b8.3 b7.8 b7.8 b7.5 b6.5 b7.1 b

Cost of goods sold

681.9 m813.2 m924.7 m987.3 m882 m998 m1.1 b1.2 b864 m1.1 b957 m1.1 b

Gross profit

2.1 b4.2 b5.6 b5.1 b6.7 b7.2 b7.2 b6.6 b6.9 b6.4 b5.5 b6 b

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


2.1 b10 b12.9 b8.2 b


2.1 b1.4 b2 b1.6 b

Current Assets

7.3 b17.7 b24.8 b20.4 b


1.2 b1.7 b2.3 b2.9 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


2 b6.4 b8.7 b6.2 b10.6 b7.4 b14 b6.3 b6.5 b9.8 b10.3 b8.7 b

Accounts Receivable

2 b3.2 b3.4 b2.9 b4.8 b5.3 b6.1 b


1.9 b2.1 b2.1 b1.9 b1.9 b2 b2 b1.9 b1.9 b1.9 b1.5 b1.4 b

Current Assets

7 b13 b15.5 b12.6 b20.1 b18.1 b25.9 b19.3 b18.4 b21.4 b21.4 b28.6 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

3.1 b12.1 b18.1 b13.5 b

Accounts Receivable

(315.3 m)(2.6 b)(1.4 b)1.2 b


(343.1 m)143 m(855 m)(488 m)

Accounts Payable

(97.7 m)(289 m)226 m47 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

785.2 m2.2 b3.7 b2.7 b4.3 b8.8 b13.4 b3.6 b7.1 b10.4 b2.7 b5.8 b

Depreciation and Amortization

75 m116 m42 m85 m129 m49 m103 m

Accounts Receivable

(810 m)(1.6 b)(191 m)190 m770 m537 m118 m


(634 m)(659 m)(14 m)(97 m)(274 m)(5 m)(14 m)
Y, 2017

Financial Leverage

2.6 x
Show all financial metrics

Gilead Sciences Operating Metrics

FY, 2016





Phase III Trials


Phase II Trials

Show all operating metrics

Gilead Sciences Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Kite PharmaAugust 28, 2017$11.9 b

Gilead Sciences Market Value History

Gilead Sciences Revenue Breakdown

Gilead Sciences Median Salaries

Source: 349 public H-1B filings from Gilead Sciences

Gilead Sciences's Web-traffic and Trends

Gilead Sciences Online and Social Media Presence

Gilead Sciences Company Life and Culture

You may also be interested in